HHS announces Phase 2 winners in data-sharing competition

HHS's Office of the National Coordinator for Health Information Technology (ONC) has announced the winners of the Phase 2 in the Move Health Data Forward Challenge, a competition for developers to build applications for the secure sharing of health information.

As a part of the ONC’s mission to improve the security and privacy of health information, the challenge pushes developers to improve the flow of health information. Before entering Phase 2, 10 Phase 1 winners were chosen and each awarded $5,000. Phase 2 will begin with developers demonstrating how their apps meet the needs for the secure sharing of health information. Each Phase 2 winner will also receive $20,000.

Phase 2 winners include:

  • CedarBridge Group: The team developed CareApprove, an app that gives patients the power to give and revoke permission to view health information. This app is compatible with electronic health records (EHRs) to maintain communication with a secure messaging system.  
  • EMR Direct: HealthToGo facilitates the deployment of apps capable collecting data from multiple sources, cutting the number of identities consumers have and giving them a single space to manage health data.
  • Foxhall Wythe: Docket stores and shares data through a secure system while promoting HIPAA compliance through user-managed access and encryption for all information.
  • Live and Leave Well: Live and Leave Well gives patients control of end of life plans with the creation of a transportable data package that can be shared using an application program interface’s direct integration.
  • Lush Group: HealthyMePHR lets patients share and give authorization to view EHRs. It also includes a resource server that provides HEART-enabled data and an authorization server to support patient policy and allow authorized users to view a patient’s records.

Following Phase 2, two Phase 3 winners will receive $50,000 awards.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup